Encapsulate develops automated tumor-on-a-chip systems to predict individual cancer patient responses to clinical treatments. The platform screens microtumors derived from patient biopsies against various regimens, delivering personalized response profiles in under seven days. This service aids oncologists in optimizing therapy selection, supports pharmaceutical R&D with pre-clinical testing, and provides researchers with access to a comprehensive patient biobank.
Funding
$3.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NFounders
Product
Problem
Predicting individual patient responses to cancer treatments remains a challenge, often leading to unnecessary chemotherapy cycles and suboptimal treatment plans. Traditional methods lack the ability to rapidly and accurately assess drug efficacy on patient-specific tumor samples.
Solution
Encapsulate offers an automated tumor-on-a-chip platform that screens microtumors derived from patient biopsies against various treatment regimens to predict individual clinical responses. The platform uses microfluidics and cell culture techniques to create a microenvironment that mimics the in vivo tumor environment. By exposing these microtumors to different drugs and drug combinations, Encapsulate can generate personalized insights on a patient's response profile in under 7 days. This approach aims to reduce unnecessary chemotherapy cycles, lower treatment costs, and enhance the success rates of personalized cancer therapies. The system enables oncologists and pharmaceutical companies to make more informed treatment decisions based on patient-specific data.
Target Audience
The primary customers are oncologists seeking to improve treatment outcomes for their patients, pharmaceutical companies developing new cancer drugs, and researchers studying cancer biology and drug mechanisms.
Features
- Automated microfluidic system for culturing and screening patient-derived microtumors
- High-throughput screening of multiple drugs and drug combinations simultaneously
- Generation of personalized response profiles within 7 days
- Customizable assays for solubility, targeting, and stability issues
- Comprehensive patient biobank with known genetic mutations and clinical response profiles
- Ability to run pre-clinical trials, patient stratification, and deep mechanism studies
- Automation systems to increase the precision and volume of tests